ArticleJapanese journal of radiology2026
Dosimetric analysis and clinical outcomes including adverse events in postoperative breast cancer irradiation involving the internal mammary lymph node region using Hybrid VMAT.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAlthough radiotherapy including the internal mammary lymph nodes (IMN) after breast surgery improves the prognosis of breast cancer, it may also increase radiation exposure to the heart and lungs due to the expanded irradiation field. Effectively and safely delivering radiation to the IMN region remains a clinical challenge. PURPOSE: At our institution, we originally developed a hybrid volumetric-modulated arc therapy (Hybrid VMAT) technique that combines conventional tangential fields with VMAT for postoperative breast cancer patients requiring irradiation to the conserved breast or chest wall and regional lymph nodes. In this study, we evaluated the safety, efficacy, and dosimetric performance of Hybrid VMAT in postoperative breast cancer patients whose treatment included the IMN region.
methodsThis retrospective study included 57 patients who received Hybrid VMAT covering the chest wall or breast and regional lymph nodes, including the IMN region, between January 2016 and March 2023. Most patients (n = 53) underwent preoperative chemotherapy, and 44 had IMN metastases at diagnosis. The standard dose was 50 Gy in 25 fractions, with a 10 Gy boost in selected cases. Dosimetric parameters (Conformity index (CI), Homogeneity index (HI), and Organ at risk (OAR) doses), clinical outcomes (local/regional control, Progression-free survival (PFS), Overall survival (OS)), and adverse events (such as pneumonitis) were evaluated using CTCAE v5.0.
resultsThe median PTV CI and HI were 1.284 and 0.100, respectively, with a median IMN HI of 0.056. Mean heart and bilateral lung doses were kept low at 4.3 and 9.1 Gy, respectively. Median follow-up was 26 months. The 2 years local control, PFS, and OS rates were 96.3%, 79.2%, and 91.4%, respectively. No ≥ Grade 2 radiation pneumonitis occurred.
conclusionThis original Hybrid VMAT technique offers a clinically viable solution for balancing adequate IMN coverage and OAR protection, enabling safe combination with systemic therapies for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.